Frontier Bets $52m On Potential Rival To Gilead's Veklury

 
• By Dexter Jie Yan
  
COVID antiviral intravenous infusion
Bofutrelvir (FB2001) is expected to fill the void of no small molecule-based antiviral treatment for hospitalized COVID-19 patients in China. • Source: Shutterstock

More from China

More from Focus On Asia